JP2020531532A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531532A5
JP2020531532A5 JP2020511375A JP2020511375A JP2020531532A5 JP 2020531532 A5 JP2020531532 A5 JP 2020531532A5 JP 2020511375 A JP2020511375 A JP 2020511375A JP 2020511375 A JP2020511375 A JP 2020511375A JP 2020531532 A5 JP2020531532 A5 JP 2020531532A5
Authority
JP
Japan
Prior art keywords
group
seq
amino acid
acid sequence
hcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020511375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531532A (ja
JP7781519B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/047286 external-priority patent/WO2019040471A1/en
Publication of JP2020531532A publication Critical patent/JP2020531532A/ja
Publication of JP2020531532A5 publication Critical patent/JP2020531532A5/ja
Priority to JP2023169177A priority Critical patent/JP2023182691A/ja
Application granted granted Critical
Publication of JP7781519B2 publication Critical patent/JP7781519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020511375A 2017-08-22 2018-08-21 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 Active JP7781519B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023169177A JP2023182691A (ja) 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548632P 2017-08-22 2017-08-22
US62/548,632 2017-08-22
PCT/US2018/047286 WO2019040471A1 (en) 2017-08-22 2018-08-21 METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023169177A Division JP2023182691A (ja) 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Publications (3)

Publication Number Publication Date
JP2020531532A JP2020531532A (ja) 2020-11-05
JP2020531532A5 true JP2020531532A5 (cg-RX-API-DMAC10.html) 2021-09-30
JP7781519B2 JP7781519B2 (ja) 2025-12-08

Family

ID=63638351

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511375A Active JP7781519B2 (ja) 2017-08-22 2018-08-21 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
JP2023169177A Pending JP2023182691A (ja) 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023169177A Pending JP2023182691A (ja) 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Country Status (6)

Country Link
US (2) US12139546B2 (cg-RX-API-DMAC10.html)
EP (1) EP3672620A1 (cg-RX-API-DMAC10.html)
JP (2) JP7781519B2 (cg-RX-API-DMAC10.html)
CA (1) CA3071387A1 (cg-RX-API-DMAC10.html)
MX (2) MX2020002057A (cg-RX-API-DMAC10.html)
WO (1) WO2019040471A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210642A1 (en) 2019-04-10 2020-10-15 Camp4 Therapeutics Corporation Methods and compositions for treating urea cycle disorders
EP4262781A4 (en) * 2020-12-16 2025-02-12 Rush University Medical Center Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders
WO2023122762A1 (en) * 2021-12-22 2023-06-29 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836308B2 (ja) 1977-02-10 1983-08-08 大塚製薬株式会社 抗体の製造方法
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
JPS56163456A (en) 1980-05-21 1981-12-16 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3515112B2 (ja) 1992-08-28 2004-04-05 ノボ ノルディスク アクティーゼルスカブ グルカゴン・レセプタ
JP2729159B2 (ja) 1994-10-31 1998-03-18 日清製粉株式会社 ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7301036B2 (en) 2003-12-19 2007-11-27 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
SI1756064T1 (sl) 2004-06-04 2008-12-31 Merck & Co Inc Derivati pirazola, sestavki vsebujoäśi takĺ ne sestavine in postopki uporabe
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
DE602005017895D1 (de) 2004-07-07 2010-01-07 Merck & Co Inc Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
AU2005269792B9 (en) 2004-07-22 2008-11-27 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
US8084489B2 (en) 2005-02-11 2011-12-27 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
CN101146763A (zh) 2005-03-30 2008-03-19 默克公司 胰高血糖素受体拮抗剂化合物、含有这种化合物的组合物以及使用方法
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
AU2007240315A1 (en) 2006-04-20 2007-11-01 Amgen Inc. GLP-1 compound/glucagon antibody compositions
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
MX2009008534A (es) 2007-02-09 2009-11-23 Metabasis Therapeutics Inc Antagonistas novedosos del receptor de glucagon.
AR070844A1 (es) 2008-03-27 2010-05-05 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
US8623818B2 (en) 2008-05-16 2014-01-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
US8436015B2 (en) 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010071750A1 (en) 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
US20110281795A1 (en) 2009-01-28 2011-11-17 Songnian Lin Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010093535A1 (en) 2009-02-12 2010-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8809579B2 (en) 2009-02-13 2014-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012188352A (ja) 2009-07-13 2012-10-04 Dainippon Sumitomo Pharma Co Ltd ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
JP2015505828A (ja) 2011-12-02 2015-02-26 イーライ リリー アンド カンパニー 抗グルカゴン抗体およびその使用
EP3194441A1 (en) 2014-09-16 2017-07-26 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof

Similar Documents

Publication Publication Date Title
Auron et al. Hyperammonemia in review: pathophysiology, diagnosis, and treatment
JP2023182691A5 (cg-RX-API-DMAC10.html)
CA2263675C (en) Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
US6011000A (en) Compositions for the treatment of blood disorders
RU2006120950A (ru) Антитело к cd40: препарат и способы
JP2022532927A5 (cg-RX-API-DMAC10.html)
JP7398958B2 (ja) 安定的抗ｏｓｍｒ抗体製剤
CN103038356A (zh) 乙酰半胱氨酸组合物及其使用方法
JP2024531151A5 (cg-RX-API-DMAC10.html)
EP2222297A1 (en) Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition
US9107894B2 (en) Formulation to improve gastrointestinal function
CN118105485B (zh) 一种稳定的抗人IL-4Rα单克隆抗体制剂
EP4530297A1 (en) Anti-asgr1 monoclonal antibody and use thereof
JP2023540025A5 (cg-RX-API-DMAC10.html)
JP7781519B2 (ja) グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
CN117159703A (zh) 含抗lag-3抗体的药物组合物及其用途
WO2017177160A1 (en) Formulation for use in a method of treatment of pain
WO2024120518A1 (zh) Il-17a抗体制剂及其用途
Savy Enteral glutamine supplementation: clinical review and practical guidelines
EP3784243B1 (en) Methotrexate for use as a medicament
HK40120457A (en) Anti-asgr1 monoclonal antibody and use thereof
CN116077650A (zh) 一种稳定的新冠中和抗体的药物组合物及其应用
US20250221954A1 (en) Methods to treat, prevent, or reduce hyperammonemia
WO2025038846A1 (en) L-arginine formulations and methods of managing pain
WO2025229631A2 (en) A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER